References
- Capodanno D, Ingala S, Calderone D, et al. Aspirin for the primary prevention of cardiovascular disease: latest evidence. Expert Rev Cardiovasc Ther. 2019;17(9):633–643.
- Baigent, Colin, Blackwell, Lisa, Collins, Rory. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet Internet. 2009;373(9678):1849–1860 doi:https://doi.org/10.1016/S0140-6736(09)60503-1. Internet: https://linkinghub.elsevier.com/retrieve/pii/S0140673609605031.
- Visseren FLJ, Mach F, Smulders YM, et al. ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J [Internet]. 2021. 2021;42(34):3227–3337. Available from: https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehab484/6358713.
- Chiarito M, Sanz-Sánchez J, Cannata F, et al. Monotherapy with a P2Y(12) inhibitor or aspirin for secondary prevention in patients with established atherosclerosis: a systematic review and meta-analysis. Lancet. 2020;395(10235):1487–1495.
- Koo B-K, Kang J, Park KW, et al. Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention (HOST-EXAM): an investigator-initiated, prospective, randomised, open-label, multicentre trial. Lancet Internet. 2021;397(10293):2487–2496. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0140673621010631.
- Capodanno D, Alfonso F, Levine GN, et al. ACC/AHA Versus ESC guidelines on dual antiplatelet therapy: JACC guideline comparison. J Am Coll Cardiol. 2018;72(23):2915–2931.
- Capodanno D, Mehran R, Valgimigli M, et al. Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention. Nat Rev Cardiol. 2018;15(8):480–496.
- Gaziano JM, Brotons C, Coppolecchia R, et al. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. Lancet. 2018;392(10152):1036–1046.
- Bowman L, Mafham M, Stevens W, et al, et al.; ASCEND Study Collaborative Group. Effects of aspirin for primary prevention in persons with diabetes mellitus. N Engl J Med. 2018;379:1529–1539.
- McNeil JJ, Nelson MR, Woods RL, et al. Effect of aspirin on all-cause mortality in the healthy elderly. N Engl J Med. 2018;379(16):1519–1528.
- Yusuf S, Joseph P, Dans A, et al. Polypill with or without aspirin in persons without cardiovascular disease. N Engl J Med. 2021;384(3):216–228.
- Angiolillo DJ, Capodanno D. Aspirin for primary prevention of cardiovascular disease in the 21st century: a review of the evidence. Am J Cardiol Internet. 2021;144(Suppl):S15–S22. Available from: http://www.ncbi.nlm.nih.gov/pubmed/33706985.
- Visseren Frank LJ, Mach F, Smulders YM, et al. ESC guidelines on cardiovascular disease prevention in clinical practice developed by the task force for cardiovascular disease prevention in clinical practice with representatives of the European society of cardiology and 12 medical societies. Eur Heart J. 2021;ehab484.
- Cosentino F, Grant PJ, Abojans V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41(2):255–323.
- Patrono C, García Rodríguez LA, Landolfi R, et al. Low-Dose aspirin for the prevention of atherothrombosis. N Engl J Med Internet. 2005;353(22):2373–2383. Available from: http://www.nejm.org/doi/abs/10.1056/NEJMra052717.
- Ricciotti E, FitzGerald GA. Prostaglandins and inflammation. Arterioscler Thromb Vasc Biol Internet. 2011;31(5):986–1000. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21508345.
- Warner TD, Nylander S, Whatling C. Anti-platelet therapy: cyclo-oxygenase inhibition and the use of aspirin with particular regard to dual anti-platelet therapy. Br J Clin Pharmacol Internet. 2011;72(4):619–633. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21320154.
- Capodanno D, Angiolillo DJ. Aspirin for primary cardiovascular risk prevention and beyond in diabetes mellitus. Circulation. 2016;134(20):1579–1594.
- Patrono C, Baigent C. Role of aspirin in primary prevention of cardiovascular disease. Nat Rev Cardiol. 2019;16(11):675–686.
- Flower R. What are all the things that aspirin does? BMJ Internet. 2003;327(7415):572–573. Available from: http://www.bmj.com/cgi/doi/10.1136/bmj.327.7415.572.
- Leonards JR. Absorption and metabolism of aspirin administered in enteric-coated tablets. JAMA J Am Med Assoc Internet. 1965;193(2):99. Available from: http://jama.jamanetwork.com/article.aspx?doi=10.1001/jama.1965.03090020013004.
- Awtry EH, Loscalzo J. Aspirin. Circulation [Internet]. 2000;101(10):1206–1218. Available from: https://www.ahajournals.org/doi/10.1161/01.CIR.101.10.1206.
- Levy G, Tsuchiya T. Salicylate accumulation kinetics in man. New Eng J Med. 1972;287(9):430–432.
- Angiolillo DJ, Bhatt DL, Lanza F, et al. Bioavailability of aspirin in fasted and fed states of a novel pharmaceutical lipid aspirin complex formulation. J Thromb Thrombolysis. 2020;49(3):337–343.
- Angiolillo DJ, Bhatt DL, Lanza F, et al. Pharmacokinetic/pharmacodynamic assessment of a novel, pharmaceutical lipid-aspirin complex: results of a randomized, crossover, bioequivalence study. J Thromb Thrombolysis Internet. 2019;48(4):554–562. Available from: http://www.ncbi.nlm.nih.gov/pubmed/31420787
- Bhatt DL, Grosser T, Dong J-F, et al. Enteric coating and aspirin nonresponsiveness in patients with type 2 diabetes mellitus. J Am Coll Cardiol Internet. 2017;69(6):603–612. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28089180.
- Gurbel PA, Bliden DP, Chaudhary R, et al. Antiplatelet effect durability of a novel, 24-hour, extended-release prescription formulation of acetylsalicylic acid in patients with type 2 diabetes mellitus. Am J Cardiol. 2016;118(12):1941–1947.
- Sørensen HT, Mellemkjaer L, Blot WJ, et al. Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin. Am J Gastroenterol. 2000;95(9):2218–2224.
- Grosser T, Fries S, Lawson JA, et al. Drug resistance and pseudoresistance. Circulation Internet. 2013;127(3):377–385. Available from: https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.112.117283.
- Kelly JP, Kaufman DW, Jurgelon JM, et al. Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product. Lancet Internet. 1996;348(9039):1413–1416. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8937281.
- Schuijt MP, Huntjens-Fleuren HWHA, de Metz M, et al. The interaction of ibuprofen and diclofenac with aspirin in healthy volunteers. BrJ Pharmacol. 2009;157(6):931–934.
- Gargiulo G, Capodanno D, Longo G, et al. Updates on NSAIDs in patients with and without coronary artery disease: pitfalls, interactions and cardiovascular outcomes. Expert Rev Cardiovasc Ther Internet. 2014;12(10):1185–1203. Available from: http://www.tandfonline.com/doi/full/10.1586/14779072.2014.964687.
- Alqahtani Z JF, Jamali F. Clinical outcomes of aspirin interaction with other non-steroidal anti-inflammatory drugs: a systematic review. J Pharm Pharm Sci. 2018;21(1s):48s–73s.
- Schjerning Olsen A-M, Gislason GH, McGettigan P, et al. Association of NSAID use with risk of bleeding and cardiovascular events in patients receiving antithrombotic therapy after myocardial infarction. JAMA Internet. 2015;313(8):805. Available from: http://jama.jamanetwork.com/article.aspx?doi=10.1001/jama.2015.0809.
- Colebatch AC, Marks JL, Van Der Heijde DM, et al. Safety of nonsteroidal antiinflammatory drugs and/or paracetamol in people receiving methotrexate for inflammatory arthritis: a Cochrane systematic review. J Rheumatol. 2012;90:62–73.
- Raber I, McCarthy CP, Vaduganathan M, et al. The rise and fall of aspirin in the primary prevention of cardiovascular disease. Lancet. 2019;393(10186):2155–2167.
- Peto R, Gray R, Collins R, et al. Randomised trial of prophylactic daily aspirin in British male doctors. BMJ Internet. 1988;296(6618):313–316. Available from: https://www.bmj.com/lookup/doi/10.1136/bmj.296.6618.313
- Physicians’ Health Study. Final report on the aspirin component of the ongoing physicians’ health study. N Engl J Med. 1989; 321: 129–135. doi:https://doi.org/10.1056/NEJM198907203210301.
- Farrell B, Godwin J, Richards S, et al. The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry Internet. 1991;54(12):1044–1054. Available from: https://jnnp.bmj.com/lookup/doi/10.1136/jnnp.54.12.1044.
- Kassoff A, Buzney S, Aspirin effects on mortality and morbidity in patients with diabetes mellitus: early treatment diabetic retinopathy study report 14. JAMA J Am Med Assoc. 1992; 268: 1292–1300. doi:https://doi.org/10.1001/jama.1992.03490100090033.
- Belch J, MacCuish A, Campbell I, et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ. 2008;337(oct16 2):a1840–a1840.
- Fowkes FGR, Price JF, Stewart MCW, et al. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. J Am Med Assoc. 2010; 303: 841–848.
- Ikeda Y, Shimada K, Teramoto T, et al. Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial. J Am Med Assoc. 2014;312(23):2510.
- Saito Y, Okada S, Ogawa H, et al. Low-Dose aspirin for primary prevention of cardiovascular events in patients with type 2 diabetes mellitus. Circulation Internet. 2017;135(7):659–670. Available from: https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.116.025760
- Côté R, Battista RN, Abrahamowicz M, et al. Lack of effect of aspirin in asymptomatic patients with carotid bruits and substantial carotid narrowing. Ann Int Med. 1995;123(9):649.
- Meade TW, Wilkes HC, Kelleher CC, et al. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet. 1998; 351: 233–241.
- Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the hypertension optimal treatment (HOT) randomised trial. Lancet. 1998;351(9118):1755–1762.
- Roncaglioni MC. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general Practice. Lancet Internet. 2001;357(9250):89–95. Available from: https://linkinghub.elsevier.com/retrieve/pii/S014067360003539X.
- Landolfi R, Marchioli R, Kutti J, et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med. 2004;350(2):114–124.
- Ridker PM, Cook NR, Lee I-M, et al. A Randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med Internet. 2005;352(13):1293–1304. Available from: http://www.nejm.org/doi/abs/10.1056/NEJMoa050613.
- Pilger E, Pilger E, Pabst E, et al. Prevention of serious vascular events by aspirin amongst patients with peripheral arterial disease: randomized, double-blind trial. J Intern Med. 2007;261(3):276–284.
- Erkan D, Harrison MJ, Levy R, et al. Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals. Arthritis Rheum. 2007;56(7):2382–2391.
- Bartolucci AA, Tendera M, Howard G. Meta-Analysis of multiple primary prevention trials of cardiovascular events using aspirin. Am J Cardiol Internet. 2011;107(12):1796–1801. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0002914911010137.
- Raju N, Sobieraj-Teague M, Hirsh J, et al. Effect of aspirin on mortality in the primary prevention of cardiovascular disease. Am J Med. 2011;124(7):621–629.
- Berger JS, Lala A, Krantz MJ, et al. Aspirin for the prevention of cardiovascular events in patients without clinical cardiovascular disease: a meta-analysis of randomized trials. Am Heart J. 2011;162(1):115–124.e2.
- Seshasai SRK, Wijesuriya S, Sivakumaran R, et al. Effect of aspirin on vascular and nonvascular outcomes: meta-analysis of randomized controlled trials. Arch Intern Med. 2012;172(3):209.
- Xie M, Shan Z, Zhang Y, et al. Aspirin for primary prevention of cardiovascular events: meta-analysis of randomized controlled trials and subgroup analysis by sex and diabetes status. Obukhov AG, editor. PLoS One Internet. 2014;9(10):e90286. Available from: https://dx.plos.org/10.1371/journal.pone.0090286
- Raju N, Sobieraj-Teague M, Bosch J, et al. Updated meta-analysis of aspirin in primary prevention of cardiovascular disease. Am J Med Internet. 2016;129(5):e35–e36. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0002934315011201.
- Guirguis-Blake JM, Evans CV, Senger CA, et al. Aspirin for the primary prevention of cardiovascular events: a systematic evidence review for the u.s. preventive services task force. Ann Int Med Internet. 2016;164(12):804. Available from: http://annals.org/article.aspx?doi=10.7326/M15-2113.
- Whitlock EP, Burda BU, Williams SB, et al. Bleeding risks with aspirin use for primary prevention in adults: a systematic review for the u.s. preventive services task force. Ann Int Med Internet. 2016;164(12):826. Available from: http://annals.org/article.aspx?doi=10.7326/M15-2112.
- Kunutsor SK, Seidu S, Khunti K. Aspirin for primary prevention of cardiovascular and all-cause mortality events in diabetes: updated meta-analysis of randomized controlled trials. Diabet Med Internet. 2017;34(3):316–327. Available from: http://doi.wiley.com/10.1111/dme.13133.
- Capodanno D, Angiolillo DJ. Tailoring duration of DAPT with risk scores. Lancet. 2017;389(10073):987–989.
- McNeil JJ, Woods RL, Nelson MR, et al. Effect of aspirin on disability-free survival in the healthy elderly. N Engl J Med Internet. 2018;379(16):1499–1508. Available from: http://www.nejm.org/doi/10.1056/NEJMoa1800722
- McNeil JJ, Wolfe R, Woods RL, et al. Effect of aspirin on cardiovascular events and bleeding in the healthy elderly. N Engl J Med. 2018;379(16):1509–1518.
- Abdelaziz HK, Saad M, Pothineni NVK, et al. Aspirin for primary prevention of cardiovascular events. J Am Coll Cardiol. 2019;73(23):2915–2929.
- Mahmoud AN, Gad MM, Elgendy AY, et al. Efficacy and safety of aspirin for primary prevention of cardiovascular events: a meta-analysis and trial sequential analysis of randomized controlled trials. Eur Heart J. 2019;40(7):607–617.
- Seidu S, Kunutsor SK, Sesso HD, et al. Aspirin has potential benefits for primary prevention of cardiovascular outcomes in diabetes: updated literature-based and individual participant data meta-analyses of randomized controlled trials. Cardiovasc. Diabetol Internet. 2019;18(1):70. Available from: https://cardiab.biomedcentral.com/articles/10.1186/s12933-019-0875-4.
- Fortuni F, Crimi G, Gritti V, et al. Primum non nocere: an updated meta-analysis on aspirin use in primary prevention of cardiovascular disease in patients with diabetes. Eur. J. Prev. Cardiol Internet. 2019;26(15):1677–1679. Available from: https://academic.oup.com/eurjpc/article/26/15/1677-1679/5925857.
- Piepoli MF, Hoes AW, Agewall S, et al. European Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J Internet. 2016;37(29):2315–2381. Available from: https://academic.oup.com/eurheartj/article-lookup/doi/10.1093/eurheartj/ehw106.
- Halvorsen S, Andreotti F, Ten Berg JM, et al. Aspirin therapy in primary cardiovascular disease prevention: a position paper of the European society of cardiology working group on thrombosis. J Am Coll Cardiol. 2014;64(3):319–327.
- Fox CS, Golden SH, Anderson C, et al. Update on prevention of cardiovascular disease in adults with type 2 diabetes mellitus in light of recent evidence: a scientific statement from the American heart association and the American diabetes association. Diabetes Care Internet. 2015;38(9):1777–1803. Available from: http://care.diabetesjournals.org/lookup/doi/10.2337/dci15-0012.
- Arnett DK, Blumenthal RS, Albert MA, et al. ACC/AHA guideline on the primary prevention of cardiovascular disease. Circulation [Internet]. 2019; Available from: https://www.ahajournals.org/doi/10.1161/CIR.0000000000000678.
- Valgimigli M, Gragnano F, Branca M, et al. P2Y12 inhibitor monotherapy or dual antiplatelet therapy after coronary revascularisation: individual patient level meta-analysis of randomised controlled trials. BMJ Internet. 2021:n1332. DOI:https://doi.org/10.1136/bmj.n1332
- O’Donoghue ML, Murphy SA, Sabatine MS. The safety and efficacy of aspirin discontinuation on a background of a p2y 12 inhibitor in patients after percutaneous coronary intervention. Circulation Internet. 2020;142(6):538–545. Available from: https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.120.046251.
- Calderone D, Capodanno D, Angiolillo DJ. An updated drug profile of ticagrelor with considerations on the treatment of patients with coronary artery disease and diabetes mellitus. Expert Rev Cardiovasc Ther Internet. 2020;18(8):449–464. Available from: https://www.tandfonline.com/doi/full/10.1080/14779072.2020.1792293.
- Gargiulo G, Windecker S, Vranckx P, et al. A Critical appraisal of aspirin in secondary prevention. Circulation Internet. 2016;134(23):1881–1906. Available from: https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.116.023952.
- Bhatt DL, Fox KAA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med Internet. 2006;354(16):1706–1717. Available from: http://www.nejm.org/doi/abs/10.1056/NEJMoa060989.
- Mauri L, Kereiakes DJ, Yeh RW, et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med Internet. 2014;371(23):2155–2166. Available from: http://www.nejm.org/doi/10.1056/NEJMoa1409312.
- Yeh RW, Kereiakes DJ, Steg PG, et al. Benefits and risks of extended duration dual antiplatelet therapy after PCI in patients with and without acute myocardial infarction. J Am Coll Cardiol Internet. 2015;65(20):2211–2221. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0735109715008086.
- Bonaca MP, Bhatt DL, Cohen M, et al. Long-Term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med Internet. 2015;372(19):1791–1800. Available from: http://www.nejm.org/doi/10.1056/NEJMoa1500857.
- Steg PG, Bhatt DL, Simon T, et al. Ticagrelor in patients with stable coronary disease and diabetes. N Engl J Med Internet. 2019;381(14):1309–1320. Available from: http://www.nejm.org/doi/10.1056/NEJMoa1908077.
- Bhatt DL, Steg PG, Mehta SR, et al. Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial. Lancet. 2019;394:1169–1180. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0140673619318872.
- Eikelboom JW, Connolly SJ, Bosch J, et al. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med Internet. 2017;377(14):1319–1330. Available from: http://www.nejm.org/doi/10.1056/NEJMoa1709118.
- Capodanno D, Bhatt DL, Eikelboom JW, et al. Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular disease. Nat Rev Cardiol Internet. 2020;17(4):242–257. Available from: http://www.nature.com/articles/s41569-019-0314-y.
- CAPRIE Steering Committee, A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet Internet. 1996;348(9038):1329–1339. doi:https://doi.org/10.1016/s0140-6736(96)09457-3. Internet: https://linkinghub.elsevier.com/retrieve/pii/S0140673696094573.
- Rollini F, Franchi F, Cho JR, et al. Cigarette smoking and antiplatelet effects of aspirin monotherapy versus clopidogrel monotherapy in patients with atherosclerotic disease: results of a prospective pharmacodynamic study. J Cardiovasc Transl Res Internet. 2014;7(1):53–63. Available from: http://link.springer.com/10.1007/s12265-013-9535-3.
- Warner TD, Armstrong PCJ, Curzen NP, et al. Dual antiplatelet therapy in cardiovascular disease: does aspirin increase clinical risk in the presence of potent P2Y12 receptor antagonists? Heart Internet. 2010;96(21):1693–1694. Available from: https://heart.bmj.com/lookup/doi/10.1136/hrt.2010.205724.
- Armstrong PCJ, Dhanji A-RA, Tucker AT, et al. Reduction of platelet thromboxane A2 production ex vivo and in vivo by clopidogrel therapy. J Thromb Haemost Internet. 2010;8(3):613–615. Available from: https://onlinelibrary.wiley.com/doi/10.1111/j.1538-7836.2009.03714.x.
- Armstrong PCJ, Leadbeater PD, Chan M V, et al. In the presence of strong P2Y12 receptor blockade, aspirin provides little additional inhibition of platelet aggregation. J Thromb Haemost Internet. 2011;9(3):552–561. Available from: https://onlinelibrary.wiley.com/doi/10.1111/j.1538-7836.2010.04160.x.
- Bhavaraju K, Georgakis A, Jin J, et al. Antagonism of P2Y 12 reduces physiological thromboxane levels. Platelets Internet. 2010;21(8):604–609. Available from: http://www.tandfonline.com/doi/full/10.3109/09537104.2010.511684.
- Björkman J-A, Zachrisson H, Forsberg G-B, et al. High-dose aspirin in dogs increases vascular resistance with limited additional anti-platelet effect when combined with potent P2Y12 inhibition. Thromb Res Internet. 2013;131(4):313–319. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0049384813000340.
- Kirkby NS, Leadbeater PDM, Chan M V, et al. Antiplatelet effects of aspirin vary with level of P2Y 12 receptor blockade supplied by either ticagrelor or prasugrel. J Thromb Haemost Internet. 2011;9(10):2103–2105. Available from: https://onlinelibrary.wiley.com/doi/10.1111/j.1538-7836.2011.04453.x.
- Vranckx P, Valgimigli M, Jüni P, et al. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-la. Lancet Internet. 2018;392(10151):940–949. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0140673618318580.
- Capodanno D. Dual antiplatelet therapy after percutaneous coronary intervention: entering the final chapter? EuroIntervention Internet. 2019;15(6):e475–e478. Available from: https://eurointervention.pcronline.com/doi/10.4244/EIJV15I6A85.
- Franzone A, McFadden EP, Leonardi S, et al. Ticagrelor alone or conventional dual antiplatelet therapy in patients with stable or acute coronary syndromes. EuroIntervention Internet. 2020;16(8):627–633. Available from: https://eurointervention.pcronline.com/doi/10.4244/EIJ-D-20-00145.
- Franzone A, McFadden E, Leonardi S, et al. Ticagrelor alone versus dual antiplatelet therapy from 1 month after drug-eluting coronary stenting. J Am Coll Cardiol Internet. 2019;74(18):2223–2234. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0735109719375345.
- Mehran R, Baber U, Sharma SK, et al. Ticagrelor with or without aspirin in high-risk patients after PCI. N Engl J Med Internet. 2019;381(21):2032–2042. Available from: http://www.nejm.org/doi/10.1056/NEJMoa1908419.
- Hahn J-Y, Bin SY, Oh J-H, et al. Effect of P2Y12 inhibitor monotherapy vs dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention. JAMA Internet. 2019;321(24):2428. Available from: https://jamanetwork.com/journals/jama/fullarticle/2736564.
- Watanabe H, Domei T, Morimoto T, et al. Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI. JAMA Internet. 2019;321(24):2414. Available from: http://jama.jamanetwork.com/article.aspx?doi=10.1001/jama.2019.8145.
- Dewilde WJ, Oirbans T, Verheugt FW, et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet Internet. 2013;381(9872):1107–1115. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0140673612621771.
- Gibson CM, Mehran R, Bode C, et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med Internet. 2016;375(25):2423–2434. Available from: http://www.nejm.org/doi/10.1056/NEJMoa1611594.
- Cannon CP, Bhatt DL, Oldgren J, et al. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med Internet. 2017;377(16):1513–1524. Available from: http://www.nejm.org/doi/10.1056/NEJMoa1708454.
- Vranckx P, Valgimigli M, Eckardt L, et al. Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial. Lancet. 2019;394(10206):1335–1343. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0140673619318720.
- Capodanno D, Di Maio M, Greco A, et al. Safety and efficacy of double antithrombotic therapy with non–vitamin k antagonist oral anticoagulants in patients with atrial fibrillation undergoing percutaneous coronary intervention: a systematic review and meta‐analysis. J Am Heart Assoc Internet. 2020;9(16). Available from: https://www.ahajournals.org/doi/10.1161/JAHA.120.017212.
- Kogame N, Guimarães PO, Modolo R, et al. Aspirin-Free prasugrel monotherapy following coronary artery stenting in patients with stable CAD. JACC Cardiovasc Interv Internet. 2020;13(19):2251–2262. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1936879820313698
- Mangano DT. Aspirin and mortality from coronary bypass surgery. N Engl J Med Internet. 2002;347(17):1309–1317. Available from: http://www.nejm.org/doi/abs/10.1056/NEJMoa020798.
- Dacey LJ, Munoz JJ, Johnson ER, et al. Effect of preoperative aspirin use on mortality in coronary artery bypass grafting patients. Ann Thorac Surg Internet. 2000;70(6):1986–1990. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0003497500021330.
- Bybee KA, Powell BD, Valeti U, et al. Preoperative aspirin therapy is associated with improved postoperative outcomes in patients undergoing coronary artery bypass grafting. Circulation Internet. 2005;112(9_supplement). Available from: https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.104.522805.
- Schunkert H, Boening A, Von Scheidt M, et al. Randomized trial of ticagrelor vs. aspirin in patients after coronary artery bypass grafting: the TiCAB trial. Eur Heart J Internet. 2019;40(29):2432–2440. Available from: https://academic.oup.com/eurheartj/article/40/29/2432/5506732.
- Kulik A, Le May MR, Voisine P, et al. Aspirin plus clopidogrel versus aspirin alone after coronary artery bypass grafting. Circulation Internet. 2010;122(25):2680–2687. Available from: https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.110.978007.
- Zhao Q, Zhu Y, Xu Z, et al. Effect of ticagrelor plus aspirin, ticagrelor alone, or aspirin alone on saphenous vein graft patency 1 year after coronary artery bypass grafting. JAMA Internet. 2018;319(16):1677. Available from: http://jama.jamanetwork.com/article.aspx?doi=10.1001/jama.2018.3197.
- Levine GN, Bates ER, Bittl JA, et al. ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American college of cardiology/American heart association task force on clinical practice guidelines: an update of the. Circulation Internet. 2016;134(10):e123–55. Available from: https://www.ahajournals.org/doi/10.1161/CIR.0000000000000404.
- Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J Internet. 2018;39(2):119–177. Available from: https://academic.oup.com/eurheartj/article/39/2/119/4095042.
- Valgimigli M, Bueno H, Byrne RA, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. Eur Heart J Internet. 2018;39(3):213–260. Available from: https://academic.oup.com/eurheartj/article/39/3/213/4095043.
- Hahn J-Y, Bin SY, Oh J-H, et al. 6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial. Lancet Internet. 2018;391(10127):1274–1284. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0140673618304938.
- Kedhi E, Fabris E, van der Ent M, et al. Six months versus 12 months dual antiplatelet therapy after drug-eluting stent implantation in ST-elevation myocardial infarction (DAPT-STEMI): randomised, multicentre, non-inferiority trial. BMJ Internet. 2018:k3793. DOI:https://doi.org/10.1136/bmj.k3793
- Camaro C, Damen SAJ, Brouwer MA, et al. Randomized evaluation of short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent: rationale and design of the REDUCE trial. Am Heart J Internet. 2016;178:37–44. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0002870316300394.
- De Luca G, Damen SA, Camaro C, et al. Final results of the randomised evaluation of short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with a new-generation stent (REDUCE trial). EuroIntervention Internet. 2019;15(11):e990–e998. Available from: https://eurointervention.pcronline.com/doi/10.4244/EIJ-D-19-00539
- Tomaniak M, Chichareon P, Onuma Y, et al. Benefit and risks of aspirin in addition to ticagrelor in acute coronary syndromes. JAMA Cardiol Internet. 2019;4(11):1092. Available from: https://jamanetwork.com/journals/jamacardiology/fullarticle/2752077.
- Storey RF. The long journey of individualizing antiplatelet therapy after acute coronary syndromes. Eur Heart J Internet. 2020;41(37):3546–3548. Available from: https://academic.oup.com/eurheartj/article/41/37/3546/5934659.
- Kim B-K, Hong S-J, Cho Y-H, et al. Effect of ticagrelor monotherapy vs ticagrelor with aspirin on major bleeding and cardiovascular events in patients with acute coronary syndrome. JAMA Internet. 2020;323(23):2407. Available from: https://jamanetwork.com/journals/jama/fullarticle/2767161.
- Watanabe H, et al. “STOPDAPT-2 ACS: one-month dual antiplatelet therapy followed by clopidogrel monotherapy in acute coronary syndrome” [Internet]. ESC. 2021. Available from: https://digital-congress.escardio.org/ESC-Congress/sessions/2843-hot-line-stopdapt-2-acs.
- Knuuti J, Wijns W,Saraste A, et al. ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2019;40(1):1–71.
- Kulik A, Ruel M, Jneid H, et al. Secondary prevention after coronary artery bypass graft surgery. Circulation Internet. 2015;131(10):927–964. Available from: https://www.ahajournals.org/doi/10.1161/CIR.0000000000000182.
- Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European association for cardio-thoracic surgery (EACTS). Eur Heart J Internet. 2021;42(5):373–498. Available from: https://academic.oup.com/eurheartj/article/42/5/373/5899003.
- Collet J-P, Thiele H, Barbato E, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J [Internet]. 2020. 2020;41(37):3495–3497. [Internet]. 2020: https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehaa575/5898842.
- Amsterdam EA, Wenger NK, Brindis RG, et al.AHA/ACC Guideline for the management of patients with non–ST-elevation acute coronary syndromes.Circulation Internet.2014;130. Available from:https://www.ahajournals.org/doi/10.1161/CIR.0000000000000134.
- O’Gara PT, Kushner FG, Ascheim DD, et al.ACCF/AHA Guideline for the management of ST-elevation myocardial infarction.Circulation Internet.2013;127. Available from:https://www.ahajournals.org/doi/10.1161/CIR.0b013e3182742cf6.
- Levine GN, Bates ER, Bittl JA, et al. ACC/AHA Guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease. J Am Coll Cardiol Internet. 2016;68(10):1082–1115. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0735109716016995
- January CT, Wann LS, Calkins H, et al. AHA/ACC/HRS focused update of the 2014 aha/acc/hrs guideline for the management of patients with atrial fibrillation: a report of the American college of cardiology/American heart association task force on clinical practice guidelines and the heart r. Circulation Internet. 2019;140(2). Available from: https://www.ahajournals.org/doi/10.1161/CIR.0000000000000665.
- Angiolillo DJ, Bhatt DL, Cannon CP, et al. Antithrombotic therapy in patients with atrial fibrillation treated with oral anticoagulation undergoing percutaneous coronary intervention. Circulation Internet. 2021;143(6):583–596. Available from: https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.120.050438.
- Ridker PM. Should aspirin be used for primary prevention in the post-statin era? N Engl J Med Internet. 2018;379(16):1572–1574. Available from: http://www.nejm.org/doi/10.1056/NEJMe1812000.
- De Berardis G, Sacco M, Evangelista V, et al. Aspirin and simvastatin combination for cardiovascular events prevention trial in diabetes (ACCEPT-D): design of a randomized study of the efficacy of low-dose aspirin in the prevention of cardiovascular events in subjects with diabetes mellitus treated w. Trials Internet. 2007;8(1):21. Available from: https://trialsjournal.biomedcentral.com/articles/10.1186/1745-6215-8-21.
- Capodanno D, Angiolillo DJ. Aspirin for primary prevention of cardiovascular disease. Lancet Internet. 2018;392(10152):988–990. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0140673618319901.
- Chan AT, Arber N, Burn J, et al. Aspirin in the chemoprevention of colorectal neoplasia: an overview. Cancer Prev Res. 2012; 5: 164–178.
- Rothwell PM, Fowkes FGR, Belch JF, et al. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet. 2011;377(9759):31–41.
- Mills EJ, Wu P, Alberton M, et al. Low-dose aspirin and cancer mortality: a meta-analysis of randomized trials. Am J Med. 2012;125(6):560–567.
- Rothwell PM, Wilson M, Elwin CE, et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet. 2010;376(9754):1741–1750.
- Ishikawa H, Wakabayashi K, Suzuki S, et al. Preventive effects of low-dose aspirin on colorectal adenoma growth in patients with familial adenomatous polyposis: double-blind, randomized clinical trial. Cancer Med. 2013;2(1):50–56.
- Rothwell PM, Price JF, Fowkes FGR, et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet Internet. 2012;379(9826):1602–1612. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0140673611617200.
- Ornelas A, Zacharias-Millward N, Menter DG, et al. Beyond COX-1: the effects of aspirin on platelet biology and potential mechanisms of chemoprevention. Cancer Metastasis Rev. 2017;36(2):289–303.
- Flossmann E, Rothwell PM. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet. 2007;369(9573):1603–1613.
- Chubak J, Whitlock EP, Williams SB, et al. Aspirin for the prevention of cancer incidence and mortality: systematic evidence reviews for the u.s. preventive services task force. Ann Int Med. 2016;164(12):814.
- Haykal T, Barbarawi M, Zayed Y, et al. Safety and efficacy of aspirin for primary prevention of cancer: a meta-analysis of randomized controlled trials. J Cancer Res Clin Oncol. 2019 145 1795–1809 .
- Coyle C, Cafferty FH, Rowley S, et al. ADD-ASPIRIN: a phase III, double-blind, placebo controlled, randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours. Contemp Clin Trials. 2016;51:56–64.
- Aspirin use to prevent cardiovascular disease: preventive medication. Available at: https://www.uspreventiveservicestaskforce.org/uspstf/draft-recommendation/aspirin-use-to-prevent-cardiovascular-disease-preventive-medication#fullrecommendationstart.
- Calderone D, Greco A, Ingala S, et al. Efficacy and safety of aspirin for cardiovascular risk prevention in younger and older age: an updated systematic review and meta-analysis. Thromb Haemost. 2021 Oct 12. DOI:https://doi.org/10.1055/a-1667-7427.
- Christensen MB, Jimenez-Solem E, Ernst MT, et al. Low-dose aspirin for primary and secondary prevention of cardiovascular events in Denmark 1998-2018. Sci Rep. 2021;11(1):13603.
- Jones WS, Mulder H, Wruck LM, et al. Comparative effectiveness of aspirin dosing in cardiovascular disease. N Engl J Med Internet. 2021;384(21):1981–1990. Available from: http://www.nejm.org/doi/10.1056/NEJMoa2102137.
- Jones WS, Mulder H, Wruck L, Aspirin dosing in cardiovascular disease. N Engl J Med Internet. 2021;385(8):764–765. Internet: http://www.nejm.org/doi/10.1056/NEJMc2110476.
- Wiebe J, Ndrepepa G, Kufner S, et al. Early aspirin discontinuation after coronary stenting: a systematic review and meta‐analysis. J Am Heart Assoc Internet. 2021;10(2). Available from: https://www.ahajournals.org/doi/10.1161/JAHA.120.018304.